{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:22:12Z","timestamp":1793316132747,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Department of Pharmaceuticals, Ministry of Chemistry and Fertilizers, Government of India"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.drudis.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T12:33:05Z","timestamp":1454934785000},"page":"481-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":209,"title":["Multidrug co-crystals: towards the development of effective therapeutic hybrids"],"prefix":"10.1016","volume":"21","author":[{"given":"Rajesh","family":"Thipparaboina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul B.","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini R.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2016.02.001_bib0515","first-page":"1","article-title":"A promising choice in hypertension treatment: fixed-dose combinations","volume":"9","author":"Wan","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0520","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2188","article-title":"The trouble with making combination drugs","volume":"5","author":"Simon","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2016.02.001_bib0525","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12039-010-0035-6","article-title":"Supramolecular chemistry and crystal engineering","volume":"122","author":"Nangia","year":"2010","journal-title":"J. Chem. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0530","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1021\/cg3002948","article-title":"Polymorphs, salts, and cocrystals: what's in a name?","volume":"12","author":"Aitipamula","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0535","series-title":"Reflection Paper on the Use of Cocrystals and other Solid State Forms of Active Substances in Medicinal Products","author":"EMA","year":"2014"},{"key":"10.1016\/j.drudis.2016.02.001_bib0540","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/cg401673z","article-title":"Mechanochemical reaction of sulfathiazole with carboxylic acids: formation of a cocrystal, a salt, and coamorphous solids","volume":"14","author":"Hu","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0545","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1107\/S0567740877006116","article-title":"The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital","volume":"33","author":"Nakao","year":"1977","journal-title":"Acta Crystallogr. B"},{"key":"10.1016\/j.drudis.2016.02.001_bib0550","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/cg301745x","article-title":"Supramolecular complexes of sulfadiazine and pyridines: reconfigurable exteriors and chameleon-like behavior of tautomers at the co-crystal\u2013salt boundary","volume":"13","author":"Elacqua","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0555","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10870-013-0480-4","article-title":"Hybrid salt-cocrystal solvate: p-coumaric acid and quinine system","volume":"44","author":"Jacobs","year":"2014","journal-title":"J. Chem. Crystallogr."},{"key":"10.1016\/j.drudis.2016.02.001_bib0560","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/cg4000439","article-title":"Understanding the effects of ionicity in salts, solvates, co-crystals, ionic co-crystals, and ionic liquids, rather than nomenclature, is critical to understanding their behavior","volume":"13","author":"Kelley","year":"2013","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0565","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1039\/c4ce00191e","article-title":"Functional hybrid co-crystals of humic substances: a growth forecast","volume":"16","author":"Lombardo","year":"2014","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0570","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1039\/C1CE05484H","article-title":"Crystal structure of a hybrid salt-cocrystal and its resolution by preferential crystallization:((\u00b1) trans-N,N\u2032-dibenzyldiaminocyclohexane)(2, 3-dichlorophenylacetic acid) 4","volume":"14","author":"Mahieux","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0575","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jpba.2015.03.003","article-title":"Molecular salts and co-crystals of mirtazapine with promising physicochemical properties","volume":"110","author":"Sarkar","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.drudis.2016.02.001_bib0580","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1039\/c2cc33855f","article-title":"Combining piracetam and lithium salts: ionic co-crystals and co-drugs?","volume":"48","author":"Braga","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.drudis.2016.02.001_bib0585","unstructured":"Cosgrove, S. et al. Astrazeneca UK Limited. Novel ticagrelor co-crystal WO Patent 2,012,164,286"},{"key":"10.1016\/j.drudis.2016.02.001_bib0590","unstructured":"Dandela, R. et al. Nutracryst Therapeutics Private Limited. Novel cocrystals\/molecular salts of mesalamine to be used as improved anti-inflammatory drug. WO Patent 2,012,090,224"},{"key":"10.1016\/j.drudis.2016.02.001_bib0595","unstructured":"Kruthiventi, A. et al. Institute Of Life Sciences, S.O.C., University Of Hyderabad. Synergistic pharmaceutical cocrystals. WO Patent 2,009,136,408"},{"key":"10.1016\/j.drudis.2016.02.001_bib0600","unstructured":"Kruthiventi, A.K. et al. Nutracryst Therapeutics Private Limited. Pharmaceutical co-crystals of quercetin. WO Patent 2,010,134,085"},{"key":"10.1016\/j.drudis.2016.02.001_bib0605","unstructured":"Reddy, J.S. et al. Nutracryst Therapeutics Private Limited. Novel cocrystals\/molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic+ anti-obesity agent. WO Patent 2,012,090,225"},{"key":"10.1016\/j.drudis.2016.02.001_bib0610","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1039\/B904616J","article-title":"Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs","volume":"11","author":"Aitipamula","year":"2009","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0615","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/jps.22434","article-title":"Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics","volume":"100","author":"Cheney","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0620","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/cg200704s","article-title":"Fast dissolving curcumin cocrystals","volume":"11","author":"Sanphui","year":"2011","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0625","first-page":"1020","article-title":"Co-crystallization of aceclofenac and paracetamol and their characterization","volume":"2","author":"Chandel","year":"2011","journal-title":"Int. J. Pharm. Life Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0630","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1002\/jps.22142","article-title":"Synthesis and preliminary characterization of sulfamethazine-theophylline co-crystal","volume":"99","author":"Lu","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0635","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/cg500668a","article-title":"Preparation and solid-state characterization of dapsone drug\u2013drug co-crystals","volume":"14","author":"Jiang","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0640","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1039\/C3CE42013B","article-title":"A sildenafil cocrystal based on acetylsalicylic acid exhibits an enhanced intrinsic dissolution rate","volume":"16","author":"Zegarac","year":"2014","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0645","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1021\/mp5004652","article-title":"Pharmaceutical cocrystals of diflunisal and diclofenac with theophylline","volume":"11","author":"Surov","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib0650","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/anie.199523111","article-title":"Supramolecular synthons in crystal engineering: a new organic synthesis","volume":"34","author":"Desiraju","year":"1995","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.drudis.2016.02.001_bib0655","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1021\/cg801249b","article-title":"OH\u22efN heterosynthon: a robust supramolecular unit for crystal engineering","volume":"9","author":"Khan","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0660","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/cg8007359","article-title":"Co-crystals of the anti-HIV drugs lamivudine and zidovudine","volume":"9","author":"Bhatt","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0665","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1039\/c3ce26765b","article-title":"Knowledge-based hydrogen bond prediction and the synthesis of salts and cocrystals of the anti-malarial drug pyrimethamine with various drug and GRAS molecules","volume":"15","author":"Delori","year":"2013","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0670","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/cg800861m","article-title":"Cambridge Structural Database analysis of molecular complementarity in cocrystals","volume":"9","author":"Fabian","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0675","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/cg800685z","article-title":"Can the formation of pharmaceutical cocrystals be computationally predicted? I. Comparison of lattice energies","volume":"9","author":"Issa","year":"2008","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0680","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1039\/b509162d","article-title":"Tape and layer structures in cocrystals of some di-and tricarboxylic acids with 4,4\u2032-bipyridines and isonicotinamide. From binary to ternary cocrystals","volume":"7","author":"Bhogala","year":"2005","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0685","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1039\/c1ce05458a","article-title":"Multicomponent solids of lamotrigine with some selected coformers and their characterization by thermoanalytical, spectroscopic and X-ray diffraction methods","volume":"13","author":"Chadha","year":"2011","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0690","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1021\/acs.cgd.5b00587","article-title":"Novel synthons in sulfamethizole cocrystals: structure\u2013property relations and solubility","volume":"15","author":"Suresh","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0695","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1107\/S2052252514004229","article-title":"Acemetacin cocrystals and salts: structure solution from powder X-ray data and form selection of the piperazine salt","volume":"1","author":"Sanphui","year":"2014","journal-title":"IUCrJ"},{"key":"10.1016\/j.drudis.2016.02.001_bib0700","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/cg801145c","article-title":"Synthon competition and cooperation in molecular salts of hydroxybenzoic acids and aminopyridines","volume":"9","author":"Sarma","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0705","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/mp0601345","article-title":"The salt-cocrystal continuum: the influence of crystal structure on ionization state","volume":"4","author":"Childs","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib0710","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1039\/c2ce26055g","article-title":"Acid-base crystalline complexes and the pKa rule","volume":"14","author":"Cruz-Cabeza","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0715","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijpharm.2011.01.030","article-title":"Hansen solubility parameter as a tool to predict cocrystal formation","volume":"407","author":"Mohammad","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib0720","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1039\/b801713c","article-title":"A rapid thermal method for cocrystal screening","volume":"10","author":"Lu","year":"2008","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0725","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1039\/B815174A","article-title":"The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome","volume":"11","author":"Friscic","year":"2009","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0730","first-page":"724","article-title":"A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram","volume":"31","author":"Hong","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2016.02.001_bib0735","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/cg070218y","article-title":"Making co-crystals the utility of ternary phase diagrams","volume":"7","author":"Chiarella","year":"2007","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0740","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1021\/cg0503346","article-title":"Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation","volume":"6","author":"Nehm","year":"2006","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0745","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/op300274s","article-title":"Current computational approaches to support pharmaceutical solid form selection","volume":"17","author":"Abramov","year":"2012","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.drudis.2016.02.001_bib0750","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1021\/cg900538g","article-title":"Predicting multicomponent crystal formation: the interplay between homomeric and heteromeric interactions","volume":"9","author":"He","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0755","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/cg401889h","article-title":"Virtual screening identifies new cocrystals of nalidixic acid","volume":"14","author":"Grecu","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0760","series-title":"Crystallization Technology Handbook","author":"Mersmann","year":"2001"},{"key":"10.1016\/j.drudis.2016.02.001_bib0765","series-title":"Crystallization","author":"Mullin","year":"2001"},{"key":"10.1016\/j.drudis.2016.02.001_bib0770","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1039\/b715396a","article-title":"Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine","volume":"10","author":"Childs","year":"2008","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0775","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jps.20578","article-title":"Pharmaceutical co-crystals","volume":"95","author":"Vishweshwar","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0780","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejps.2014.06.001","article-title":"Generation of 1:1 carbamazepine:nicotinamide cocrystals by spray drying","volume":"62","author":"Patil","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0785","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.ejpb.2013.04.022","article-title":"High-shear granulation as a manufacturing method for cocrystal granules","volume":"85","author":"Rehder","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib0790","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1007\/s11095-010-0273-9","article-title":"Cocrystallization and simultaneous agglomeration using hot melt extrusion","volume":"27","author":"Dhumal","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2016.02.001_bib0795","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3390\/pharmaceutics3030582","article-title":"Application of twin screw extrusion in the manufacture of cocrystals, part I: four case studies","volume":"3","author":"Daurio","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2016.02.001_bib0800","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1039\/C3FD00153A","article-title":"Application of twin screw extrusion to the manufacture of cocrystals: scale-up of AMG 517-sorbic acid cocrystal production","volume":"170","author":"Daurio","year":"2014","journal-title":"Faraday Discuss."},{"key":"10.1016\/j.drudis.2016.02.001_bib0805","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1021\/op800228h","article-title":"A novel method for large-scale synthesis of lamivudine through cocrystal formation of racemic lamivudine with (S)-(\u2212)-1,1\u2032-Bi (2-naphthol)[(S)-(binol)]","volume":"13","author":"Roy","year":"2009","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.drudis.2016.02.001_bib0810","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1021\/cg500547m","article-title":"Design space for polymorphic co-crystallization: incorporating process model uncertainty and operational variability","volume":"14","author":"Yu","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0815","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/op4003399","article-title":"Development and scale-up of cocrystals using resonant acoustic mixing","volume":"18","author":"Am Ende","year":"2014","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.drudis.2016.02.001_bib0820","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1039\/C4CE00154K","article-title":"From discovery to scale-up: \u03b1-lipoic acid: nicotinamide co-crystals in a continuous oscillatory baffled crystalliser","volume":"16","author":"Zhao","year":"2014","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0825","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1107\/S010827010605520X","article-title":"Escitalopram oxalate: co-existence of oxalate dianions and oxalic acid molecules in the same crystal","volume":"63","author":"Harrison","year":"2007","journal-title":"Acta Crystallogr. C: Struct. Chem."},{"key":"10.1016\/j.drudis.2016.02.001_bib0830","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/mp0700054","article-title":"Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding","volume":"4","author":"Karki","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib0835","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.inoche.2007.10.024","article-title":"Unprecedented sodium\u2013oxygen clusters in the solid-state structure of trisodium hydrogentetravalproate monohydrate: a model for the physiological activity of the anticonvulsant drug Epilim\u00ae","volume":"11","author":"Petrusevski","year":"2008","journal-title":"Inorg. Chem. Commun."},{"key":"10.1016\/j.drudis.2016.02.001_bib0840","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4155\/ppa.12.29","article-title":"The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents","volume":"1","author":"Almarsson","year":"2012","journal-title":"Pharm. Pat. Anal."},{"key":"10.1016\/j.drudis.2016.02.001_bib0845","series-title":"Pharmaceutical Salts and Co-crystals","first-page":"318","article-title":"Co-crystals: commercial opportunities and patent considerations","author":"Hoffman","year":"2012"},{"key":"10.1016\/j.drudis.2016.02.001_bib0850","unstructured":"Buschmann, D. et al. Laboratorios Del. Dr S.A. Esteve. Co-crystals of duloxetine and co-crystal formers for the treatment of pain. EP Patent 2,123,626"},{"key":"10.1016\/j.drudis.2016.02.001_bib0855","unstructured":"Buschmann, D. et al. Laboratorios Del. Dr S.A. Esteve. Co-crystals of tramadol and paracetamol. EP Patent 2,199,274"},{"key":"10.1016\/j.drudis.2016.02.001_bib0860","unstructured":"Buschmann, H.H. et al. Laboratorios Del. Dr S.A. Esteve. Co-crystals of tramadol and NSAIDS. EP Patent 2,177,215"},{"key":"10.1016\/j.drudis.2016.02.001_bib0865","unstructured":"Plata Salaman, C.R. and Tesson, N., Laboratorios Del. Dr S.A. Esteve Co-crystals of tramadol and coxibs. EP Patent 2,488,169"},{"key":"10.1016\/j.drudis.2016.02.001_bib0870","unstructured":"Plata Salaman, C.R. et al. Laboratorios Del. Dr S.A. Esteve. Co-crystals of venlafaxine and celecoxib. EP Patent 2,340,818"},{"key":"10.1016\/j.drudis.2016.02.001_bib0875","unstructured":"Plata, S.C.R. et al. Laboratorios Del. Dr S.A. Esteve, Crystalline forms of sartans like telmisartan with beta blockers. EP 2649996 A1"},{"key":"10.1016\/j.drudis.2016.02.001_bib0880","unstructured":"Sowa, C. et al. Basf (China) Company Limited, Co-crystals of cyprodinil and dithianon. US20140205641 A1"},{"key":"10.1016\/j.drudis.2016.02.001_bib0885","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1107\/S0108270196014783","article-title":"Methanol solvate of the 1:1 molecular complex of trimethoprim and sulfadimidine","volume":"53","author":"Bettinetti","year":"1997","journal-title":"Acta Crystallogr. C: Struct. Chem."},{"key":"10.1016\/j.drudis.2016.02.001_bib0890","first-page":"193","article-title":"Molecular complexes of sulfonamides. 2.1:1 complexes between drug molecules: sulfadimidine-acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid","volume":"22","author":"Caira","year":"1992","journal-title":"J. Chem. Crystallogr."},{"key":"10.1016\/j.drudis.2016.02.001_bib0895","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1107\/S0108270197000425","article-title":"Trimethoprim-sulfadimidine 1:2 molecular complex monohydrate","volume":"53","author":"Sardone","year":"1997","journal-title":"Acta Crystallogr. C: Struct. Chem."},{"key":"10.1016\/j.drudis.2016.02.001_bib0900","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1107\/S0108270195003295","article-title":"A 2:1 molecular complex of theophylline and 5-fluorouracil as the monohydrate","volume":"51","author":"Zaitu","year":"1995","journal-title":"Acta Crystallogr. C: Struct. Chem."},{"key":"10.1016\/j.drudis.2016.02.001_bib0905","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S1600536809031031","article-title":"Theophylline-gentisic acid (1\/1)","volume":"65","author":"Aitipamula","year":"2009","journal-title":"Acta Crystallogr. Sect. E Struct. Rep. Online"},{"key":"10.1016\/j.drudis.2016.02.001_bib0910","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<478::AID-JPS5>3.0.CO;2-5","article-title":"Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex","volume":"89","author":"Bettinetti","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0915","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1039\/C1CE06310C","article-title":"Covalent assistance to supramolecular synthesis: modifying the drug functionality of the antituberculosis API isoniazid in situ during co-crystallization with GRAS and API compounds","volume":"14","author":"Lemmerer","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0920","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1107\/S0108270112045866","article-title":"Multicomponent pharmaceutical cocrystals: furosemide and pentoxifylline","volume":"68","author":"Stepanovs","year":"2012","journal-title":"Acta Crystallogr. C: Struct. Chem."},{"key":"10.1016\/j.drudis.2016.02.001_bib0925","first-page":"414","article-title":"Cocrystal formation of paracetamol with indomethacin and mefenamic acid: an efficient approach to enhance solubility","volume":"5","author":"Pathak","year":"2013","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.drudis.2016.02.001_bib0930","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1039\/b501304f","article-title":"Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients","volume":"36","author":"Vishweshwar","year":"2005","journal-title":"Chem. Commun."},{"key":"10.1016\/j.drudis.2016.02.001_bib0935","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1039\/c0ce00842g","article-title":"Drug-drug co-crystals: temperature-dependent proton mobility in the molecular complex of isoniazid with 4-aminosalicylic acid","volume":"13","author":"Grobelny","year":"2011","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0940","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1021\/cg500388s","article-title":"Origin of deteriorated crystal plasticity and compaction properties of a 1:1 cocrystal between piroxicam and saccharin","volume":"14","author":"Chattoraj","year":"2014","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0945","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/cg501009c","article-title":"Cocrystallization of nutraceuticals","volume":"15","author":"Sinha","year":"2015","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib0950","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drudis.2007.10.010","article-title":"Plant-derived compounds in clinical trials","volume":"13","author":"Saklani","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2016.02.001_bib0955","series-title":"Clinical Aspects of Functional Foods and Nutraceuticals","author":"Ghosh","year":"2014"},{"key":"10.1016\/j.drudis.2016.02.001_bib0960","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.colsurfb.2015.07.046","article-title":"Micellar carriers for the delivery of multiple therapeutic agents","volume":"135","author":"Thipparaboina","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.drudis.2016.02.001_bib0965","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1021\/ja203002w","article-title":"Cocrystals of homochiral and achiral amino acid zwitterions with Li+ salts: water-stable zeolitic and diamondoid metal\u2013organic materials","volume":"133","author":"Ong","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2016.02.001_bib0970","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1021\/mp400571a","article-title":"Improving lithium therapeutics by crystal engineering of novel ionic cocrystals","volume":"10","author":"Smith","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib0975","doi-asserted-by":"crossref","DOI":"10.1039\/c4ce00409d","article-title":"Ionic co-crystals of racetams: solid\u2013state properties enhancement of neutral active pharmaceutical ingredients via addition of Mg2+ and Ca2+ chlorides","author":"Grepioni","year":"2014","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0980","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1039\/c3ce41539b","article-title":"Novel pharmaceutical compositions through co-crystallization of racetams and Li+ salts","volume":"15","author":"Wouters","year":"2013","journal-title":"CrystEngComm"},{"key":"10.1016\/j.drudis.2016.02.001_bib0985","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/mp.2015.4","article-title":"Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics","volume":"20","author":"Alda","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2016.02.001_bib0990","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0885-3924(99)00135-9","article-title":"The safety and efficacy of a single dose (500mg or 1g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer","volume":"19","author":"Crosby","year":"2000","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.drudis.2016.02.001_bib0995","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2012.09.034","article-title":"Drug nanocrystals in the commercial pharmaceutical development process","volume":"453","author":"Moschwitzer","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib1000","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1002\/ange.201002588","article-title":"Pharmaceutical nano-cocrystals: sonochemical synthesis by solvent selection and use of a surfactant","volume":"122","author":"Sander","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.drudis.2016.02.001_bib1005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep06575","article-title":"Continuous engineering of nano-cocrystals for medical and energetic applications","volume":"4","author":"Spitzer","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2016.02.001_bib1010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2013.12.016","article-title":"Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs","volume":"87","author":"De Smet","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2016.02.001_bib1015","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1021\/cg301293r","article-title":"Supramolecular synthons: validation and ranking of intermolecular interaction energies","volume":"12","author":"Dunitz","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.drudis.2016.02.001_bib1020","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1039\/c3cp55390f","article-title":"Role of supramolecular synthons in the formation of the supramolecular architecture of molecular crystals revisited from an energetic viewpoint","volume":"16","author":"Shishkin","year":"2014","journal-title":"Phys. Chem. Chem. Phys."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616300265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644616300265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:24:38Z","timestamp":1761222278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644616300265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1359644616300265"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2016.02.001","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidrug co-crystals: towards the development of effective therapeutic hybrids","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}